2026-07-31 Posted by TideChem view:102
An androgen receptor antibody is a research or diagnostic reagent designed to recognize the androgen receptor protein, commonly abbreviated as AR. These antibodies are used to detect AR expression, localization, molecular variants and selected post-translational modifications in cells and tissues.
Common applications include immunohistochemistry, Western blotting, immunofluorescence, immunoprecipitation and chromatin immunoprecipitation. AR antibodies are especially important in prostate cancer research, but they are also used in breast cancer, endocrine biology, reproductive research and studies of androgen insensitivity.
Selecting an appropriate antibody requires more than choosing a familiar clone. The epitope, AR isoform, sample type, fixation method and experimental application all affect performance.
The androgen receptor is a ligand-activated transcription factor belonging to the nuclear receptor family. It is encoded by the AR gene on the X chromosome.
The full-length human androgen receptor contains several functional regions:
Testosterone and dihydrotestosterone are the principal endogenous androgen ligands. Ligand binding changes AR conformation, promotes nuclear localization and supports receptor binding to androgen response elements in DNA.
Once associated with chromatin, AR recruits coactivators or corepressors and regulates genes involved in development, metabolism, cell differentiation and proliferation.
The reviewed human AR entry in UniProt describes the receptor as a ligand-activated transcription factor. The NCBI AR Gene record provides information about its conserved domains and transcript variants.
An androgen receptor antibody binds to a specific region, or epitope, of the AR protein. Depending on its design, the antibody may recognize:
The phrase “total AR antibody” does not always mean that every AR isoform will be detected. It usually means the antibody recognizes AR regardless of one selected modification, but actual isoform coverage depends on where the epitope is located.
The immunogen and epitope should therefore be reviewed before an antibody is selected.
In most product catalogs and research papers, an androgen receptor antibody is a detection reagent rather than a therapeutic antibody.
AR is primarily an intracellular protein. Conventional therapeutic antibodies do not readily cross intact cell membranes and enter the cytoplasm or nucleus. Clinically used AR-directed therapies are generally small-molecule antagonists, androgen-synthesis inhibitors or other approaches capable of influencing intracellular signaling.
Experimental intracellular antibodies, antibody fragments and delivery technologies are being investigated, but they should not be confused with routine anti-AR antibodies used for IHC or Western blotting.
The AR domain recognized by an antibody determines which molecular forms can be detected.
An antibody against the N-terminal domain may recognize full-length AR and some truncated variants that retain the N-terminus.
This makes N-terminal antibodies useful for broad AR detection, but they may not distinguish full-length AR from C-terminally truncated variants.
Antibodies directed against the ligand-binding domain or another C-terminal epitope generally recognize full-length AR.
They may fail to detect splice variants that lack the C-terminal ligand-binding domain.
Variant-specific antibodies are developed against unique amino acid sequences generated by alternative splicing.
AR-V7 is a clinically studied splice variant with a distinct C-terminal sequence and no conventional ligand-binding domain. A valid AR-V7 antibody must recognize the variant-specific region without substantially cross-reacting with full-length AR or other proteins.
Phospho-specific AR antibodies recognize a phosphorylated residue only when the modification is present.
These antibodies require particularly careful validation. Specificity should ideally be tested using phosphatase treatment, phospho-null mutants, kinase perturbation or a suitable peptide competition experiment.
Full-length androgen receptor contains both the DNA-binding and ligand-binding domains. Its transcriptional activity is normally regulated by androgen binding, although other signaling pathways can also influence receptor activity.
AR-V7 retains the N-terminal and DNA-binding regions but has a distinct C-terminus and lacks the conventional ligand-binding domain. It can regulate a subset of AR-associated genes without steroid binding.
The current NCBI AR record lists AR-V7 as a reviewed transcript variant with a shorter, distinct C-terminus.
This structural difference has direct consequences for antibody selection:
Published AR-V7 studies also demonstrate why a variant-specific label should not be accepted without experimental validation. Some AR-V7 antibodies have produced nonspecific staining or additional Western blot bands. One detailed IHC validation study is available from PubMed Central.
Immunohistochemistry is used to examine AR expression and localization in formalin-fixed, paraffin-embedded tissue.
In many AR-positive tissues and tumors, biologically relevant staining is predominantly nuclear. However, cytoplasmic staining may also occur because of receptor localization, fixation effects or nonspecific binding.
An antibody validated for Western blotting is not automatically suitable for IHC. Formalin fixation can mask epitopes, create crosslinks and alter protein conformation. Antigen retrieval conditions may strongly affect signal intensity.
Important IHC variables include:
Clinical tissue studies should use a fully validated assay with documented positive and negative controls.
Western blotting detects AR in denatured protein extracts and provides approximate molecular-size information.
Full-length human AR often migrates near 110 kDa, although apparent size can vary because of sequence length, modification and electrophoresis conditions. AR-V7 has commonly been reported near 75–80 kDa.
A band at the expected size is supportive but does not prove specificity. An antibody can recognize both AR and unrelated proteins of similar molecular mass.
Specificity should be evaluated through knockdown, knockout, overexpression, independent antibodies or another orthogonal method.
Immunocytochemistry and immunofluorescence can reveal AR localization in cultured cells.
Ligand exposure may promote nuclear accumulation, while hormone-depleted conditions may alter localization and expression. Fixation and permeabilization must preserve the target epitope while allowing the antibody to reach intracellular AR.
Fluorescence intensity should not be interpreted as an absolute protein concentration unless the assay has been calibrated and shown to operate within a quantitative range.
Immunoprecipitation can isolate AR from cell lysates for interaction studies, Western blotting or mass spectrometry.
An effective immunoprecipitation antibody must recognize AR in a relatively native state. An antibody that performs well against denatured protein on a Western blot may fail to capture native AR.
Researchers should consider whether the epitope is exposed in the receptor complex and whether the antibody interferes with interacting proteins.
Chromatin immunoprecipitation is used to study AR binding to genomic regions.
A ChIP-compatible antibody must recognize crosslinked chromatin-associated AR with adequate specificity and capture efficiency. Antibody performance can be influenced by fixation, chromatin fragmentation and epitope accessibility.
ChIP results should include input controls, suitable negative regions and biologically relevant positive target regions. ChIP-seq experiments also require appropriate library and sequencing controls.
Because AR is intracellular, flow-cytometric detection generally requires fixation and permeabilization.
Surface-staining protocols are not sufficient. Antibody conjugation, fixation chemistry and permeabilization conditions must be optimized together.
AR signaling is central to normal prostate biology and many stages of prostate cancer.
AR antibodies are used to study:
Total AR expression does not always equal pathway activity. A tumor may express AR protein while showing altered chromatin binding, cofactor interactions or target-gene transcription.
AR IHC should therefore be interpreted together with histology, molecular context and other biomarkers. For mechanistic studies, protein detection can be combined with RNA analysis, chromatin assays and measurements of AR-regulated genes.
AR is expressed in a proportion of breast cancers, including many estrogen receptor-positive tumors and some triple-negative breast cancers.
IHC can be used to evaluate nuclear AR expression and intratumoral heterogeneity. However, study-specific scoring thresholds vary, and AR positivity should not automatically be treated as proof of androgen dependence or therapeutic response.
Research studies should report:
Differences in these variables can contribute to inconsistent results across publications.
A monoclonal antibody recognizes one principal epitope. It can provide good specificity and consistent performance when the clone is well characterized.
However, recognition of a single epitope makes performance more sensitive to fixation, mutation or epitope masking.
A polyclonal antibody preparation contains antibodies recognizing multiple epitopes.
This can increase signal strength or tolerance to partial epitope damage. However, polyclonal reagents may have greater lot-to-lot variation and a higher risk of nonspecific binding.
Recombinant antibodies are produced from defined antibody sequences. They can offer improved manufacturing consistency and long-term clone availability.
Recombinant production does not eliminate the need for validation. A reproducibly manufactured antibody can still cross-react or perform poorly in a particular application.
Begin with the biological question rather than the product description.
Determine whether the experiment requires total AR, full-length AR, AR-V7 or a phosphorylated form.
Check whether the epitope is located in the N-terminal, DNA-binding or C-terminal region. For splice-variant studies, map the epitope against every relevant isoform.
Select an antibody validated for the intended method. IHC, Western blot, ChIP, IP and flow cytometry impose different antigen conditions.
An antibody validated for human AR may not recognize mouse, rat or another species. Sequence similarity alone does not guarantee equivalent performance.
FFPE tissue, frozen tissue, cultured cells and purified protein may require different antibodies and protocols.
Host species affects secondary-antibody selection and multiplexing design. Isotype information is also important for immunoprecipitation and control selection.
Sodium azide, bovine serum albumin, glycerol or other formulation components may interfere with conjugation, live-cell work or downstream assays. A carrier-free format may be required for direct labeling.
Look for uncropped blots, knockout controls, multiple tissues or cell lines, expected localization and independent publications.
Vendor data are useful starting points, but they do not replace validation under the laboratory’s own conditions.
An antibody is not universally “validated.” It is validated for a target, sample type, preparation method and application.
The International Working Group for Antibody Validation has described several complementary validation strategies:
A summary of these validation approaches is available in Nature Methods.
Genetic controls are especially informative. If the signal remains unchanged after confirmed AR knockout, the antibody is probably detecting another target.
Common AR-positive prostate cancer models include LNCaP and VCaP cells. The 22Rv1 model is frequently used in AR-variant research, while LNCaP95 has been used in full-length AR and AR-V7 studies.
PC-3 and DU145 cells are commonly treated as AR-negative controls. However, cell-line identity, passage history and culture conditions should be verified because expression can change across laboratories.
A strong validation plan may include:
A no-primary control can reveal secondary-antibody or detection-system background, but it does not establish primary-antibody specificity.
AR is a nuclear receptor, so nuclear signal is often the most biologically relevant finding. Nevertheless, interpretation depends on cell type, ligand exposure and experimental conditions.
Cytoplasmic staining may reflect unliganded receptor, altered trafficking, degradation or technical background. It should not automatically be discarded or accepted.
For IHC, report both the proportion of stained cells and signal intensity. An H-score or another predefined scoring system can improve consistency, but the scoring method must be documented.
For image analysis, segmentation quality is critical. Stromal, inflammatory and benign epithelial cells can express different amounts of AR and should not be included in tumor measurements unintentionally.
An AR antibody measures protein abundance or localization, depending on the assay. It does not directly measure transcriptional activity.
AR signaling can be influenced by:
A complete mechanistic study may combine AR protein detection with target-gene expression, reporter assays, ligand manipulation and chromatin occupancy measurements.
Confirm species reactivity, sample expression and application compatibility. Review transfer conditions for Western blotting and antigen retrieval for IHC.
Excessive fixation can mask epitopes, while protein degradation can eliminate the target. Include a confirmed positive control in every run.
Additional bands may represent isoforms, degradation products, post-translationally modified AR or nonspecific targets.
Compare knockout or knockdown lysates, test a second antibody and review whether the detected sizes correspond to known variants.
Reduce excessive antibody concentration, improve blocking and washing, and examine secondary-antibody specificity.
For tissue staining, endogenous enzyme activity, autofluorescence and nonspecific Fc interactions may contribute to background.
Review ligand conditions, fixation, permeabilization and subcellular fractionation data. Compare the result with a second antibody or another localization method.
Record the clone and lot number. Revalidate new lots before replacing a critical reagent, especially for polyclonal antibodies and long-term clinical research studies.
To support reproducibility, report:
The phrase “anti-AR antibody was used” is not enough for another laboratory to reproduce the experiment.
An antibody labeled for research use only should not be treated as a validated clinical diagnostic reagent.
Clinical implementation requires analytical validation for the intended specimen, laboratory, platform and interpretation method. Accuracy, precision, sensitivity, specificity, reproducibility, stability and scoring must be established under applicable quality and regulatory requirements.
An AR IHC result should not independently determine patient treatment unless the assay and interpretation have appropriate clinical evidence and authorization for that use.
It detects an epitope within the AR protein. Depending on the epitope, it may recognize total AR, full-length AR, an AR splice variant or a modified form.
AR can be present in the cytoplasm and nucleus. Androgen binding generally promotes nuclear localization and transcriptional regulation.
Full-length AR commonly migrates near 110 kDa, although the observed size can vary. AR-V7 has often been reported near 75–80 kDa.
Only if its epitope is retained in AR-V7. An N-terminal antibody may detect both full-length AR and AR-V7, while a C-terminal antibody generally will not detect AR-V7.
There is no universally best antibody. Selection depends on species, epitope, tissue preparation, retrieval method and required AR isoform. The antibody must be validated in the intended IHC workflow.
Not automatically. Western blotting detects denatured protein, while IHC examines fixed tissue. Application-specific validation is required.
An AR-knockout or confirmed AR-negative sample is a strong negative control. PC-3 cells are often used, but their identity and AR status should be confirmed locally.
No. A research AR antibody is primarily a detection or capture reagent. Antiandrogen drugs are pharmacological agents that inhibit AR signaling.
An androgen receptor antibody is an important tool for studying AR expression, localization, splice variants and signaling. Its performance depends on epitope location, sample preparation and experimental application.
For reliable results, researchers should identify the AR form they need to measure, select an application-appropriate antibody and validate specificity using genetic or orthogonal controls. This is particularly important for AR-V7 and phospho-specific antibodies, where cross-reactivity can lead to incorrect biological conclusions.